Skip to main content

and
  1. Article

    Open Access

    Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

    In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membra...

    Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf in EJNMMI Research (2023)

  2. Article

    Open Access

    Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study

    Cerebral glucose hypometabolism is a typical hallmark of Alzheimer’s disease (AD), usually associated with ongoing neurodegeneration and neuronal dysfunction. However, underlying pathological processes are no...

    Heike Endepols, Marta Anglada-Huguet, Eckhard Mandelkow in Molecular Neurobiology (2022)

  3. Article

    Open Access

    [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

    PSMA imaging is frequently used for monitoring of androgen deprivation therapy (ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable properties for tumor localization after biochemica...

    Felix Dietlein, Peter Mueller, Carsten Kobe in Molecular Imaging and Biology (2021)

  4. Article

    Open Access

    Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

    We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a novel 18F-labeled PSMA-ligand for PET/CT imaging of prostate cancer.

    Melanie Hohberg, Carsten Kobe, Philipp Krapf, Philipp Täger in EJNMMI Research (2019)

  5. Article

    Open Access

    Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents

    The recent implementation of PET with prostate specific membrane antigen (PSMA)-specific radiotracers into the clinical practice has resulted in the significant improvement of accuracy in the detection of pros...

    Heike Endepols, Agnieszka Morgenroth, Boris D. Zlatopolskiy, Philipp Krapf in BMC Cancer (2019)

  6. Article

    Open Access

    In vivo Molecular Imaging of Glutamate Carboxypeptidase II Expression in Re-endothelialisation after Percutaneous Balloon Denudation in a Rat Model

    The short- and long-term success of intravascular stents depends on a proper re-endothelialisation after the intervention-induced endothelial denudation. The aim of this study was to evaluate the potential of in ...

    Heike Endepols, Felix M. Mottaghy, Sakine Simsekyilmaz, Jan Bucerius in Scientific Reports (2018)

  7. Article

    Open Access

    Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

    Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [68Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent...

    Markus Dietlein, Carsten Kobe, Georg Kuhnert in Molecular Imaging and Biology (2015)